collection
https://read.qxmd.com/read/26604307/engineering-high-affinity-pd-1-variants-for-optimized-immunotherapy-and-immuno-pet-imaging
#1
JOURNAL ARTICLE
Roy L Maute, Sydney R Gordon, Aaron T Mayer, Melissa N McCracken, Arutselvan Natarajan, Nan Guo Ring, Richard Kimura, Jonathan M Tsai, Aashish Manglik, Andrew C Kruse, Sanjiv S Gambhir, Irving L Weissman, Aaron M Ring
Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has shown remarkable clinical success in the treatment of cancer. However, antibodies have inherent limitations that can curtail their efficacy in this setting, including poor tissue/tumor penetrance and detrimental Fc-effector functions that deplete immune cells...
November 24, 2015: Proceedings of the National Academy of Sciences of the United States of America
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.